Castle Biosciences Surges with 33% Test Growth, Upgrades 2025 Outlook

Introduction

Castle Biosciences, Inc. (Nasdaq: CSTL) is a molecular diagnostics company focused on improving patient care through gene expression profile (GEP) tests. As of August 5, 2025, its share price was $20.00, reflecting a 30.55% increase, with daily trading volume at 195,487 shares on the Nasdaq exchange. The company's products are designed to guide management decisions related to risk in dermatologic cancers, Barrett’s esophagus, and uveal melanoma.

Corporate Structure

Founded in 2008, Castle Biosciences employs between 501 and 1,000 individuals. Its headquarters are located in Friendswood, Texas, with laboratory operations in Phoenix, Arizona, and Pittsburgh, Pennsylvania. The organization fosters a culture that emphasizes collaboration, integrity, innovation, and excellence.

Cancer diagnostics by David Clode

Recent Developments and News

• On August 4, 2025, Castle Biosciences reported second quarter 2025 revenue of $86 million, an increase attributed to a 33% rise in core test reports (DecisionDx-Melanoma and TissueCypher) compared to the previous year. The company updated its full-year 2025 revenue guidance to a range of $310 million to $320 million, up from $287 million to $297 million.
• DecisionDx-Melanoma received Breakthrough Device designation from the U.S. Food and Drug Administration in July 2025, highlighting its potential role in melanoma prognostication.
• Executive management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
• In June 2025, CEO Derek Maetzold was recognized as a 2025 Most Admired CEO by the Houston Business Journal.

Financial and Strategic Analysis

Castle Biosciences has recorded revenue growth and an increase in testing volume, supported by its portfolio of five proprietary GEP assays: DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, MyPath Melanoma, and TissueCypher Barrett’s Esophagus. These tests address critical clinical questions, such as metastasis risk and precision staging. The company emphasizes research and development, as evidenced by over 150 peer-reviewed publications and more than 300,000 test reports delivered since its inception. By integrating advanced biomarker technologies and artificial intelligence, Castle seeks to enhance its market presence.

Market Position and Industry Context

Situated within the biotechnology research sector, Castle Biosciences occupies a specialized position in cancer diagnostics. Its personalized approach to disease management contrasts traditional staging methods by incorporating tumor biology into risk assessment. As healthcare providers increasingly adopt precision medicine, Castle’s GEP tests address needs in melanoma, squamous cell carcinoma, uveal melanoma, and Barrett’s esophagus. The company faces competition from other molecular diagnostics firms, but its clinical validation and regulatory recognitions contribute to its competitive differentiation.

tl;dr

On August 4, 2025, Castle Biosciences reported Q2 revenue of $86 million, with test reports increasing by 33% year-over-year, and raised its 2025 guidance to $310 million–$320 million. DecisionDx-Melanoma received FDA Breakthrough Device designation in July, and management will present at Canaccord Genuity on August 12. CEO Derek Maetzold was recognized as a 2025 Most Admired CEO. The company's future outlook depends on continued adoption of its tests and market expansion.